Fecal microbiota transplantation: an update on the advances in the treatment of complex diseases

Carlotta Magrì¹, Giuliana Calabrese¹, Letizia Masi², Sara Troisi¹, Federica di Vincenzo¹, Pierluigi Puca¹, Cristina Graziani², Loris R. Lopetuso^2,3,4, Valentina Petito²

¹Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
²Centro per le Malattie dell’Apparato Digerente (CeMAD), UOS di Malattie Infiammatorie Croniche Intestinali, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy.
³Dipartimento di Medicina e Scienze dell’Invecchiamento, Università degli studi “G. D’Annunzio”, Chieti-Pescara, Chieti, Italy.
⁴Center for Advanced Studies and Technology (CAST), Università degli studi “G. D’Annunzio”, Chieti-Pescara, Chieti, Italy.

Nutr Cur 2023; 02: e001

DOI: 10.57625/nec.2022.23

ABSTRACT

In addition to its proven effectiveness in the treatment of recurrent Clostridium difficile infections (rCDI), fecal microbiota transplantation (FMT) is on the rise to become one of the most studied innovative therapies for the treatment of several complex diseases. This review aims to discuss the many promising applications of FMT in intestinal diseases such as inflammatory bowel diseases (IBD) and extraintestinal diseases such as neuropsychiatric disorders, metabolic syndrome, and autoimmune diseases. For each disease group, preclinical data will be presented in addition to clinical trial evidence.

Corresponding author:

Valentina Petito
valentina.petito@unicatt.it

To cite this article: Magrì Carlotta, Calabrese Giuliana, Masi Letizia, Troisi Sara, Di Vincenzo Federica, Puca Pierluigi, Graziani Cristina, Lopetuso Loris R., Petito Valentina. Fecal microbiota transplantation: an update on the advances in the treatment of complex diseases. Nutr Cur 2022; 01: e131 - DOI: 10.57625/nec.2022.23

Publication history:

Submission date: 8th Dec, 2022
Revised on: 12th Dec, 2022
Accepted on: 15th Dec, 2022
Published online: 10th Jan, 2023

This work is licensed under a Creative Common Attribution-NonCommercial-ShareAlike 4.0 International License

Category: Review
Topic: Fecal microbial transplantation

Related articles

Nutr Cur 2023; 02: e012

Fecal microbiota transplantation: lights and shadows of a new weapon against inflammatory bowel diseas

Treatment of inflammatory bowel disease (IBD) remains one of the most critical public health issues, mostly due to its wide global prevalence and dramatic impact on patients' quality of life.

Andrea Piccioni, Federico Rosa, Federica Manca, Davide Antonio Della Polla, Martina Petrucci, Benedetta Simeoni, Marcello Covino

Mar 08th, 2023

Nutr Cur 2023; 02: e010

Inositol supplementation in patients taking lithium or valproic acid: strengthening the multidisciplinary approach

Dear Editor, I’ve read with great interest the review recently published by Kamenov et al1 about the importance of inositol supplementation in recovering side effects induced by mood stabilizers and anticonvulsant drugs.

Francesca Pacitti

Feb 13th, 2023

Nutr Cur 2023; 02: e007

Electronic cigarettes’ effects on respiratory health

Electronic cigarettes (ECs) are electronic nicotine delivery systems (ENDS). ECs have been sold as a safer alternative to traditional cigarettes due to the lack of tobacco combustion since 2006...

Tonia Magrì, Bruno Iovene, Luca Richeldi

Feb 03rd, 2023

Nutrimentum et Curae focuses on all issues related to body and mind health maintenance, and the search for all strategies – pharmacological and non-pharmacological – to find optimal nutritional and behavioral patterns for the population.

Nutrimentum et Curae is an Indicon S.r.l. Società Benefit (SB) project • Powered by Rocket Social Studio
Via Saffi, 10 – 20123 Milan • PEC: indicon@pec.it • Share capital 100.000,00 € i.v. • P.IVA/CF 11647700969 • REA MI n. 2616861 • Privacy Policy